- HOME
- Vol.52 No.11
- CLINICA NEUROL, 52: 1143|1146, 2012
- Vol.52 No.11 contents
Symposium 2
iPS cell transplantation for ischemic brain
Koji Abe, M.D., Toru Yamashita, M.D. and Hiromi Kawai, M.D.
Department of Neurology, Okayama University Medical School
Stroke is a major neurologic disorder. Induced pluripotent stem (iPS) cells can be produced from basically any part of patients, with high reproduction ability and pluripotency to differentiate into various types of cells, suggesting that iPS cells can provide a hopeful therapy for cell transplantation. However, transplantation of iPS cells into ischemic brain has not been reported. In this study, we showed that the iPS cells fate in a mouse model of transient middle cerebral artery occlusion (MCAO). Undifferentiated iPS cells (5∗10(5)) were transplanted into ipsilateral striatum and cortex at 24 h after 30 mins of transient MCAO. Behavioral and histologic analyses were performed at 28 day after the cell transplantation. To our surprise, the transplanted iPS cells expanded and formed much larger tumors in mice postischemic brain than in sham-operated brain. The clinical recovery of the MCAO+iPS group was delayed as compared with the MCAO+PBS (phosphate-buffered saline) group. iPS cells formed tridermal teratoma, but could supply a great number of Dcx-positive neuroblasts and a few mature neurons in the ischemic lesion. iPS cells have a promising potential to provide neural cells after ischemic brain injury, if tumorigenesis is properly controlled.
Full Text of this Article in PDF (366K)
(CLINICA NEUROL, 52: 1143|1146, 2012)
key words: iPS cell, cerebral infarction, Yamanaka 4 factors, MMP9
(Received: 24-May-12)